Figitumumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | IGF-1 receptor |
| Clinical data | |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6462H9948N1736O2020S54 |
| Molar mass | 146008.04 g·mol−1 |
| (what is this?) (verify) | |
Figitumumab (previously CP-751871) is a monoclonal antibody[1] targeting the insulin-like growth factor-1 receptor that was investigated for the treatment of various types of cancer, for example adrenocortical carcinoma[2] and non-small cell lung cancer (NSCLC).[3]
This drug was being developed by Pfizer, but they ceased development of the drug in January 2011 and has stopped its manufacture.[4]
- ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Figitumumab, American Medical Association.
- ^ Haluska P, Worden F, Olmos D, Yin D, Schteingart D, Batzel GN, et al. (March 2010). "Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma". Cancer Chemotherapy and Pharmacology. 65 (4): 765–73. doi:10.1007/s00280-009-1083-9. PMC 2875253. PMID 19649631.
- ^ Gualberto A, Karp DD (July 2009). "Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer". Clinical Lung Cancer. 10 (4): 273–80. doi:10.3816/CLC.2009.n.038. PMID 19632947.
- ^ "Cancer sufferer fears future without 'life-saver' drug". BBC News. July 2014.